To Shuxuetong joint Breviscapine early diabetic nephropathy Clinical observation x test, measurement data using the test. 2 Results 2.1 efficacy evaluation standards markedly: symptoms and signs disappeared, and urinary albumin excretion rate is less than 201xg/min. Effective: symptoms, signs, reduce the urinary albumin excretion rate more than 50% compared with before treatment. Invalid: symptoms, signs of improvement in urinary albumin excretion rate is not to achieve effective standards or aggravate. 2.2 curative effect treatment group, 12 cases markedly effective in 17 cases, 3 cases, total effective rate was 90.6%; control group, eight cases markedly effective in 12 cases, invalid lO cases, total effective rate was 66. 7%. 2 The total effective rate, the difference was significant O. o1). Test indexes After treatment, fasting blood glucose 2.3 before and after treatment, urine B-microglobulin and urinary albumin excretion rate decreased significantly, the difference was significant) < O. 01); only fasting blood glucose after treatment than before treatment in the control group decreased differences were significant (P <0.01). Table 1. Table 1 before and after treatment FPG, urinary B-microglobulin, UREA change (+ J1 Note: before and after treatment, P <0.01, 2.4 lipid levels in the serum lipid profiles in the treatment group before and after treatment compared with treatment before a significant improvement, the difference was significant (P <0.05). Table 2. 487 · Zunyi Medical College 32 Table 2 the two groups before and after treatment lipid levels change f) group of cholesterol (mmol triglyceride (mmo children) of high-density lipoprotein (mm0l Note: before and after treatment,}, P <0.05. discussion of diabetic nephropathy is a serious complication of diabetes, but also the leading cause of death for people with diabetes. studies have shown that: glomerular high perfusion pressure and high filtration, interstitial proliferation in glomerular mesangial cells, glomerular basement membrane thickening and permeability increase is the main reason of the disease development [I], and diabetic nephropathy there are endothelial cells damage, increased blood coagulation activity and inhibition of fibrinolysis activation, treatment of diabetic nephropathy is first of all to the regulation of vascular endothelial function, to prevent the proliferation of glomerular basement membrane, the regulation of vascular smooth muscle tone, spasm, followed by lipid-lowering, anticoagulant, and enhance the fibrinolytic Fu Pi to improve the hypercoagulable state. Shuxuetong injection with anticoagulant, promote fibrinolysis and reduce the role of platelet aggregation, lowering its main ingredients leech, earthworm Poxue the stasis, the meridians, diuretic to eliminate the effect of urinary protein Court motherland medicine to treat kidney disease medicine that can improve the kidney disease cycle, protection of endothelial tissue, and promote repair to reduce kidney damage, recovery of renal function. erigeron injection on live m circulation Tongluo pain, can effectively expand the blood vessels, improve microcirculation. against platelet aggregation, lower blood viscosity [31. may improve glomerular capillary endothelial function, breviscapine parenteral solution can significantly reduce urinary protein excretion of [4 total flavonoids] of Breviscapine aldose reductase inhibitors can reduce proteinuria, effectively protect the kidney. In addition, in recent years, the study found that platelet function in patients with DN microangiopathy, and Flavonoids of Breviscapine antiplatelet and the role of cell aggregation in order to effectively treat DN. author of previous animal experiments observed Breviscapine effective inhibition of rat proximal tubule cells under oxidative stress in high glucose environment and sodium potassium ATPase activity of the enhanced [5I feed. In this study, joint sparse blood through the treatment effect is worthy of further explored.